NC-VERANEX
12.10.2021 15:02:07 CEST | Business Wire | Press release
Veranex , the first concept-to-commercialization global service provider dedicated to the MedTech industry, today announced the acquisition of IMMR , a leading preclinical science organization that provides preclinical research, pathology evaluation and surgical training services to medical technology innovators. IMMR is located in Paris, France.
Formed in June 2021 with global growth investor Summit Partners , Veranex provides the global medical technology industry with comprehensive and integrated solutions and services that accelerate the product life cycle to help improve the lives of patients everywhere. As a result of this acquisition, Veranex gains state-of-the-art, FDA-inspected and AAALAC-accredited facilities and extensive in-house expertise, enhancing Veranex’s services for preclinical studies worldwide.
“We are excited to welcome the world-class and market leader IMMR to Veranex,” said Patrick K. Donnelly , Executive Chairman at Veranex. “Veranex is focused on the needs of the MedTech industry and this acquisition enhances our long-term ability to meet the end-to-end needs of MedTech companies in one organization. Veranex’s clients will benefit from IMMR’s 30-plus years of experience in the design and conduct of preclinical studies, expertise in complex cardiovascular and non-cardiovascular procedures, and state-of-the-art surgical suites and husbandry facilities, all unparalleled for leading successful completion of sophisticated studies with novel interventional or surgical technologies.”
“As part of a combined company with a full range of product development, regulatory, and market access expertise, our partnership with Veranex complements our vision to help clients achieve their objectives and advance important MedTech innovations that significantly improve patient care,” said IMMR Founding Partner and Scientific Director Luc Behr , D.V.M., Ph.D. “IMMR adds another dimension of expertise and services to Veranex to enable and accelerate research in the industry.”
IMMR’s unique, highly efficient, and full service approach — with studies that are carefully planned, expertly conducted to the highest ethical standards, and professionally documented — saves money and reduces time to market.
“IMMR excels in procedures ranging from early feasibility studies through to GLP studies to support global regulatory approvals,” added IMMR Founding Partner and Scientific Director Nicolas Borenstein , D.V.M., Ph.D. “With our expert team of professionals, our worldwide clientele enjoys high success rates with their medical technology innovations.”
For this transaction, financial advisors were Clearwater International and Cain Brothers , a division of KeyBanc Capital Markets, and Gide Loyrette Nouel , a leading international law firm located in Paris, served as legal counsel. Financial terms of the transaction were not disclosed.
About Veranex
Veranex is the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry. Offering expert guidance from concept through to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time, while its integrated and comprehensive solutions unify the entire development process. For more information, visit VeranexSolutions.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom